GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma AS (NAS:ASND) » Definitions » Cyclically Adjusted PS Ratio

ASND (Ascendis Pharma AS) Cyclically Adjusted PS Ratio : 99.13 (As of May. 30, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Ascendis Pharma AS Cyclically Adjusted PS Ratio?

As of today (2025-05-30), Ascendis Pharma AS's current share price is $163.57. Ascendis Pharma AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was $1.65. Ascendis Pharma AS's Cyclically Adjusted PS Ratio for today is 99.13.

The historical rank and industry rank for Ascendis Pharma AS's Cyclically Adjusted PS Ratio or its related term are showing as below:

ASND' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 82.22   Med: 123.54   Max: 170.19
Current: 98.62

During the past years, Ascendis Pharma AS's highest Cyclically Adjusted PS Ratio was 170.19. The lowest was 82.22. And the median was 123.54.

ASND's Cyclically Adjusted PS Ratio is ranked worse than
95.37% of 497 companies
in the Biotechnology industry
Industry Median: 5.33 vs ASND: 98.62

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Ascendis Pharma AS's adjusted revenue per share data for the three months ended in Mar. 2025 was $1.818. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $1.65 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Ascendis Pharma AS Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Ascendis Pharma AS's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma AS Cyclically Adjusted PS Ratio Chart

Ascendis Pharma AS Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 131.76 93.78

Ascendis Pharma AS Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 138.39 123.72 125.66 93.78 94.18

Competitive Comparison of Ascendis Pharma AS's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Ascendis Pharma AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascendis Pharma AS's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Ascendis Pharma AS's Cyclically Adjusted PS Ratio falls into.


;
;

Ascendis Pharma AS Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Ascendis Pharma AS's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=163.57/1.65
=99.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ascendis Pharma AS's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Ascendis Pharma AS's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=1.818/120.2000*120.2000
=1.818

Current CPI (Mar. 2025) = 120.2000.

Ascendis Pharma AS Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 0.091 100.300 0.109
201509 0.097 100.200 0.116
201512 0.086 99.800 0.104
201603 0.056 100.200 0.067
201606 0.051 100.600 0.061
201609 0.052 100.200 0.062
201612 0.036 100.300 0.043
201703 0.012 101.200 0.014
201706 0.015 101.200 0.018
201709 0.016 101.800 0.019
201712 0.009 101.300 0.011
201803 0.001 101.700 0.001
201806 0.001 102.300 0.001
201809 0.001 102.400 0.001
201812 0.284 102.100 0.334
201903 0.141 102.900 0.165
201906 0.077 102.900 0.090
201909 0.052 102.900 0.061
201912 0.058 102.900 0.068
202003 0.051 103.300 0.059
202006 0.034 103.200 0.040
202009 0.062 103.500 0.072
202012 0.012 103.400 0.014
202103 0.017 104.300 0.020
202106 0.023 105.000 0.026
202109 0.024 105.800 0.027
202112 0.097 106.600 0.109
202203 0.133 109.900 0.145
202206 0.117 113.600 0.124
202209 0.271 116.400 0.280
202212 0.434 115.900 0.450
202303 0.641 117.300 0.657
202306 0.913 116.400 0.943
202309 0.911 117.400 0.933
202312 2.655 116.700 2.735
202403 1.832 118.400 1.860
202406 0.676 118.500 0.686
202409 1.116 118.900 1.128
202412 3.045 118.900 3.078
202503 1.818 120.200 1.818

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Ascendis Pharma AS  (NAS:ASND) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Ascendis Pharma AS Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma AS's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascendis Pharma AS Business Description

Traded in Other Exchanges
Address
Tuborg Boulevard 12, Hellerup, DNK, DK-2900
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.